The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possess an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapy drug treatment and so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better drug efficacy and safety e.g. Zydelig, Gazyva, Abemaciclib and KTE-C19.
To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of mechanism of action are Bruton’s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.
Country cross sectional market estimate and forecast for the geography segment has been included in the scope of the report.
The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drug for the treatment of mantle cell lymphoma we need to cater competitive landscape. Latest merger or acquisition and purchase of promising drug molecules are mentioned in the company profile section. The major players in global mantle cell lymphoma treatment market are Celgene Corporation Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc. Johnson and Johnson and F.Hoffman La Roche Ltd.
Simulation-based medical training efficiently offers training to medical professionals for performing critical procedures on an interactive platform. This also assists surgeons and medical staff in improving clinical skills, emergency care delivery and augment safety outcomes. Patient simulation solutions offer high-fidelity equipment with features such as breathing pattern, sounds, pulse measurement, blood pressure monitoring, EKG and others. This market is driven by ethical sensitivity about patient subjects, and growing concerns on patient safety.
High-risk clinical departments such as intensive care, emergency response, anesthesia, neonatal care, and cath labs would most prominently benefit from adoption of mannequin-based simulation for training and education of healthcare personnel. This market may experience challenges in terms of restrained government funds.
Mannequin-based simulation finds the widest use in academics. Simulated medical training offers advantages such as safe training modules, hands-on education in interactive settings, and extensive training for emergency response. Challenges such as patient safety concerns are efficiently overcome through mannequin-based simulation tools such as high fidelity mannequins, patient safety virtual reality simulation and others. These solutions are being increasingly used in settings such as hospital rooms, emergency settings, and simulation facilities as training solutions and have demonstrated impressive results. Underutilization of simulation technologies due to complexity in assembly and operation had been a hindrance for growth in the past; however, it is being overcome by introduction of automated instruction and better user interfaces.
North America and Europe are the largest regional markets for mannequin-based simulation. Growth in adoption of simulation technologies and rise in demand for minimally invasive procedures are the prime factors driving the mannequin-based simulation market in these regions. In addition, success in use of mannequin-based simulation in delivering patient safety is a strong driving factor in the developed markets. On the other hand, limits on funding in such activities by siphoning the resources to other areas such as technological development in surgical procedures may hold back the growth of this market. Asia-Pacific and Latin America markets will undergo rapid growth during the forecast period. The demand for simulation solutions for training and education purposes will be high in these regions.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Mantle Cell Lymphoma Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Mechanism of Action
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
